ClinicalTrials.gg
Status unknownNCT03922659THEDUpdated Mar 22, 2021

Efficacy of Repetitive Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy on Heroin Dependence

An interventional study of Transcranial magnetic stimulation and Cognitive behavioral therapy in Heroin Dependence, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Heroin dependence is one of most common substance dependence, which brings great burden on health worldwide. Heroin dependence may lead to immunosuppression and cognitive impairments. Once heroin dependence is developed, it will be difficult to recover and easy to relapse. Although many efforts had been made in the treatment of heroin dependence, the annual recurrence of heroin dependence with traditional therapies would be up to 90%. Repetitive transcranial magnetic stimulation (rTMS) on the dorsolateral prefrontal cortex (DLPFC) or cognitive behavioral therapy (CBT) each alone was reported to have some effect on preventing from relapse of substance dependence. In order to test whether combined therapy of high frequency rTMS (hf-rTMS) with CBT is better for preventing from relapse of heroin dependence, we recruit patients with heroin dependence to participate this study. The study is a factorial designed and the patients will be assigned into one of the following six groups randomly: (1) regular treatment (symptomatic treatment) with blank TMS; (2) regular treatment (RT) with blank TMS and CBT; (3) RT with right DLPFC hf-rTMS; (4) RT with right DLPFC hf-rTMS and CBT; (5) RT with left DLPFC hf-rTMS; (6) RT with left DLPFC hf-rTMS and CBT. TMS was given 5 days per week for total 2 weeks using uniform scheme (5 seconds of 10Hz stimulation per train, 30 trains per day with inter-train interval of 20 seconds). CBT will be given once per week for total 8 weeks. The patients will be followed up for 6 months. Recurrence of heroin dependence, duration of abstention, heroin/drug intake, craving for heroin and other cognitive psychological assessments will be recorded and compared among the 6 treatment groups and the efficacy of combined therapy of rTMS with CBT will be evaluated in our study.

02

Conditions studied

  • Heroin Dependence

Browse trials for

Keywords

  • Heroin dependence, transcranial magnetic stimulation, cognitive behavioral therapy
03

In context

Heroin Dependence

90 studies on the registry are indexed under Heroin Dependence; 1 is open to participants now.

This study's planned enrollment of 300 is above the median of 87 across 57 interventional studies indexed under Heroin Dependence.

Browse Heroin Dependence studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 483 studies on the registry; 283 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis as heroin dependence according to criteria
  • No definite history of neurological diseases and psychological problems
  • Volunteer to participate the study, cooperate to be followed up

Exclusion criteria

Exclusion Criteria:

  • Acute withdrawal state and CIWA score > 9
  • With other neurological diseases and psychological problems
  • With ever brain trauma and damage
  • With other psychological medications or other substance dependence
  • With other to have transcranial magnetic stimulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Placebo comparator
    Regular treatment (symptomatic treatment) with blank TMS

    Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

  • Active comparator
    Regular treatment (RT) with blank TMS and CBT

    Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

  • Active comparator
    RT with right DLPFC hf-rTMS

    Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

  • Active comparator
    RT with right DLPFC hf-rTMS and CBT

    Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

  • Active comparator
    RT with left DLPFC hf-rTMS

    Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

  • Active comparator
    RT with left DLPFC hf-rTMS and CBT

    Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)

    Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy

Interventions

  • Combination productTranscranial magnetic stimulation and Cognitive behavioral therapy

    Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

06

What researchers measure

Primary outcomes

  1. Recurrence of heroin dependence

    The rate of relapse of heroin dependence after discharge from hospital

    Time frame: 1 month

  2. Recurrence of heroin dependence

    The rate of relapse of heroin dependence after discharge from hospital

    Time frame: 2 month

  3. Recurrence of heroin dependence

    The rate of relapse of heroin dependence after discharge from hospital

    Time frame: 3 month

  4. Recurrence of heroin dependence

    The rate of relapse of heroin dependence after discharge from hospital

    Time frame: 6 month

Secondary outcomes

  1. Duration of abstinence

    The total time or period without any intake of heroin during follow-ups

    Time frame: 6 months

  2. Heroin consumption

    Diaries of heroin intake in different time of the follow-ups

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

  3. Craving for heroin

    Craving assessment for heroin by Heroin Craving Questionnaire (HCQ) ranging from 0 to 175. Higher score of HCQ indicates more desire for heroin.

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

  4. Craving for heroin

    Craving assessment by Visual Analogue Scale (VAS) for heroin desire ranging 0 to 10. Higher score indicates more desire for heroin.

    Time frame: 2weeks, 1 month, 2 months, 3 months and 6 months

  5. Cognitive assessment

    Cognitive assessment by Montreal Cognitive Assessment (MoCA) ranging from 0 to 30. Lower score indicates worse cognitive function.

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

  6. Psychological assessment - Anxiety

    Psychological assessment by Generalized Anxiety Disorder-7 (GAD-7) ranging from 0 to 21. Higher score indicates more severer anxiety.

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

  7. Psychological assessment - Depression

    Psychological assessment by Patient Health Questionnaire-9 (PHQ-9) ranging from 0 to 27. Higher score indicates more severer depression.

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

  8. Psychological assessment - Sleep

    Psychological assessment by Pittsburgh Sleep Quality Index (PSQI) ranging from 0 to 21. Higher score indicates worse sleep.

    Time frame: 2 weeks, 1 month, 2 months, 3 months and 6 months

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
08

References and documents

Publications

  • Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009 Jun 13;373(9680):2041-53. doi: 10.1016/S0140-6736(09)60660-7. PubMed 19524780 ↗
  • Makani R, Pradhan B, Shah U, Parikh T. Role of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of Addiction and Related Disorders: A Systematic Review. Curr Drug Abuse Rev. 2017;10(1):31-43. doi: 10.2174/1874473710666171129225914. PubMed 29189190 ↗
  • Shen Y, Cao X, Tan T, Shan C, Wang Y, Pan J, He H, Yuan TF. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. Biol Psychiatry. 2016 Aug 1;80(3):e13-4. doi: 10.1016/j.biopsych.2016.02.006. Epub 2016 Feb 12. No abstract available. PubMed 26995024 ↗
  • Herremans SC, Vanderhasselt MA, De Raedt R, Baeken C. Reduced intra-individual reaction time variability during a Go-NoGo task in detoxified alcohol-dependent patients after one right-sided dorsolateral prefrontal HF-rTMS session. Alcohol Alcohol. 2013 Sep-Oct;48(5):552-7. doi: 10.1093/alcalc/agt054. Epub 2013 May 24. PubMed 23709633 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2019 (actual). Primary completion is estimated for Dec 2021, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 22, 2019
StartActual
Jun 30, 2019
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2021
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03922659
Responsible party
Ying Peng (Professor, Director of Department of Neurology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Apr 22, 2019
Start date
Jun 30, 2019
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Mar 22, 2021

Study contacts

Ying Peng, MD, PhD
Contact
pengy2@mail.sysu.edu.cn
+86-13380051581
Hongxuan Wang, MD, PhD
Contact
wanghx8@mail.sysu.edu.cn
+86-13824498978

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion